4D Molecular Therapeutics, Inc.FDMTNASDAQ

Revenue (LTM)

-100.0% YoY

Net Income (LTM)

$-140M

+12.9% YoY

Free Cash Flow

$-109M

Revenue CAGR (5Y)

—

Marginsimproving

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	18	3↓82.7%	21↑562.3%	0↓99.8%	0
Gross Profit	-43	-77↓78.0%	-76↑1.0%	0↑100.0%	0
Operating Income	-71	-110↓54.3%	-113↓2.6%	-188↓66.4%	-160↑15.1%
Net Income	-71	-107↓50.7%	-101↑6.2%	-161↓59.5%	-140↑12.9%
EBITDA	-70	-108↓54.2%	-109↓1.0%	-181↓66.7%	-160↑11.9%
EPS Diluted	-2.46	-3.12↓26.8%	-2.58↑17.3%	-2.98↓15.5%	-2.42↑18.8%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	153	52↓65.8%	249↑375.8%	149↓40.1%	60↓59.7%
Total Current Assets	256	221↓14.0%	297↑34.5%	435↑46.6%	413↓5.0%
Total Assets	353	262↓25.9%	340↑29.8%	560↑64.9%	567↑1.1%
Total Current Liabilities	16	16↓3.7%	19↑20.5%	29↑53.8%	44↑50.9%
Total Liabilities	34	31↓11.3%	32↑5.1%	50↑55.3%	61↑22.6%
Total Equity	319	231↓27.5%	308↑33.1%	511↑65.9%	506↓1.0%
Total Debt	16	16↓2.0%	15↓9.0%	25↑67.7%	21↓13.0%
Net Debt	-137	-36↑73.5%	-234↓547.1%	-125↑46.8%	-39↑68.9%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-69	-87↓25.4%	-76↑12.6%	-135↓77.6%	-109↑18.9%
Capital Expenditure	-9	-12↓26.6%	-3↑76.0%	-4↓36.6%	0
Free Cash Flow	-78	-98↓25.5%	-79↑20.0%	-138↓76.1%	-109↑21.2%
Stock-Based Comp	14	17↑24.1%	20↑14.9%	26↑32.8%	22↓15.7%
Net Change in Cash	-124	-101↑18.7%	197↑295.5%	-100↓150.7%	-89↑10.7%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance